EAPCI Column

DOI:

EAPCI Focus on the EAPCI Scientific Documents and Initiatives Committee

An interview with the Chair Giulio Stefanini

Figure 1

Figure 1.

What is the role of the committee?

Any proposal for scientific documents received by the EAPCI must be submitted to the Scientific Documents and Initiatives Committee (SDIC) for approval prior to their development. Together with my Co-Chair Nieves Gonzalo and committee members, the SDIC reviews all document proposals and makes approval or rejection recommendations. These recommendations are then reviewed and confirmed by the EAPCI Executive Committee. The responsibilities of the committee include the screening and validation of solicited and unsolicited documentation proposals as well as the identification of topics suitable for EAPCI scientific documents. Once the topic has been selected and approved, the committee is responsible for the administrative supervision and coordination of Writing Groups, coordination of the declarations of interest process for appointed authors as well as coordination of the review process.

How do EAPCI scientific documents benefit the community?

The key benefit of EAPCI scientific documents is to provide guidance for clinical management on topics not covered, or not covered in sufficient detail, in the existing or upcoming ESC Clinical Practice Guidelines. Whilst their topics and scope should not overlap with those of guidelines, scientific documents may complement them by providing more in-depth information in specific areas that cannot be expanded upon in guidelines. Our scientific documents evaluate scientific evidence, explore expert consensus in a structured way and, typically, include very practical advice for daily management of the topics discussed.

How are topics chosen and how can EAPCI members contribute?

Any EAPCI member may submit a proposal for a scientific document; any proposal received is subject to the robust and transparent review process of the SDIC followed by the EAPCI Executive Committee. Furthermore, one of the roles of the SDIC is to identify areas of unmet need and propose these topics to the EAPCI Executive Committee for consideration.

What are the upcoming topics?

  • Percutaneous coronary intervention in patients with cancer
  • Follow-up strategies in patients after transcatheter aortic valve replacement
  • Day-clinic care for percutaneous cardiovascular interventions
  • Sex-related considerations in mitral and tricuspid valve interventions

News

  • Attending ESC Congress 2023 in Amsterdam from August 25th-28th? Come to the ESC Plaza and find out more about EAPCI.
  • Not yet an EAPCI member? Join online https://www.escardio.org/EAPCI
Volume 19 Number 5
Aug 7, 2023
Volume 19 Number 5
View full issue

Suggested by Cory

Editorial

10.4244/EIJ-E-25-00022 Sep 15, 2025
An ongoing quest to discern the optimal antithrombotic therapy after TAVI
Hayashida K and Iwata J
free

Translational research

10.4244/EIJ-D-24-01000 Sep 15, 2025
DurAVR – a novel biomimetic balloon-expandable transcatheter valve for TAVI, valve-in-valve TAVI and redo-TAVI
Meier D et al
open access

Research Correspondence

10.4244/EIJ-D-25-00255 Sep 15, 2025
Redo-TAVI with the ACURATE platform for failure of short-frame transcatheter heart valves
Tarantini G et al

Editorial

10.4244/EIJ-E-25-00038 Sep 15, 2025
Evolving cutoff values for optimising left main stenting with intravascular imaging
de la Torre Hernandez J
free

State-of-the-Art

10.4244/EIJ-D-24-00992 Sep 15, 2025
Antithrombotic therapy in complex percutaneous coronary intervention
Castiello D et al
free

Flashlight

10.4244/EIJ-D-25-00121 Sep 15, 2025
Calcium mapping by 3DStent technology
Amabile N and Benamer H

Original Research

10.4244/EIJ-D-24-01066 Sep 15, 2025
VARC-HBR criteria validation in TAVI patients on oral anticoagulation
Overduin D et al
Trending articles
56.1

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
56.1

Original Research

10.4244/EIJ-D-25-00331 Jul 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
55.7

State-of-the-Art

10.4244/EIJ-D-24-00992 Sep 15, 2025
Antithrombotic therapy in complex percutaneous coronary intervention
Castiello D et al
free
28.25

Clinical research

10.4244/EIJ-D-19-01006 Aug 7, 2020
Coronary collaterals and myocardial viability in patients with chronic total occlusions
Schumacher S et al
free
X

PCR
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved